|

Imaging Histone Deacetylase in the Heart

RECRUITINGN/ASponsored by Massachusetts General Hospital
Actively Recruiting
PhaseN/A
SponsorMassachusetts General Hospital
Started2018-09-07
Est. completion2026-03-01
Eligibility
Age18 Years – 85 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT03549559

Summary

The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone deacetylase targeted radioligand, in patients with aortic stenosis, individuals with diabetes, and healthy volunteers.

Eligibility

Age: 18 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

Group 1: Healthy Volunteers (n = 30)

* Healthy adults with no known history of medical disease
* Age 18-85 years
* No history cardiovascular disease
* Ability to provide informed consent

Group 2: Patients with Diabetes (n = 16)

* Age 18-85 years
* Diagnosis of diabetes
* Echocardiogram within last 12 months showing no evidence of left ventricular hypertrophy or hemodynamic findings consistent with heart failure with preserved ejection fraction
* Ability to provide informed consent

Group 3: Patients with Aortic Stenosis (n = 50)

* Age 18-85 years
* Echocardiogram or cardiac MRI scan within last 12 months documenting left ventricular hypertrophy and degenerative calcific aortic stenosis
* Ability to provide informed consent

Exclusion Criteria:

* Known contraindication to MRI

Conditions5

Aortic Valve StenosisDiabetesHeart DiseaseHeart Failure With Normal Ejection FractionLeft Ventricular Hypertrophy

Locations1 site

Massachusetts General Hospital
Boston, Massachusetts, 02114
David Sosnovik, MD

Browse More Trials

Heart Disease trialsDiabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.